Eccogene
PrivateLast Round
Strategic
Nov 9, 2023
Total Funding Raised
$224.8M
Momentum Score
25 /100
Company Overview
Eccogene is a clinical-stage biopharmaceutical company founded in 2018 with operations in Shanghai, China, and Boston, USA. The company focuses on discovering and developing best-in-class, next-generation small molecule therapeutics for chronic cardiometabolic and inflammatory diseases. Eccogene's primary business is creating oral therapies to treat conditions such as obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The company's pipeline includes multiple candidates, with its most prominent asset being ECC5004 (also known as AZD5004), an oral GLP-1 receptor agonist. In November 2023, Eccogene entered into an exclusive global licensing agreement with AstraZeneca to develop and commercialize ECC5004. The company is venture capital-backed, having completed a Series B financing round in June 2023.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Clinical Trials, Biotechnology
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Eccogene Comps
Public and private peers based on sector, stage, and business model.
Eccogene Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Nov 9, 2023 | ||||
| Series B | Jun 12, 2023 | ||||
| VC Round | Dec 22, 2020 | ||||
| Series A | Sep 6, 2018 |
Key People
Founding team and executive leadership
Eccogene Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| New Alliance Capital | Series B |
| TF Capital | Series A |
| 健壹资本 | Series A |
| Huajin Capital | Series B |
| Huagai Capital | VC Round |
| Delos Capital Partners | Series B, VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 8, 2026
Job posting indicates company is pre-IPO.
- Jan 5, 2025
Dr. Jai Patel appointed as the new Chief Medical Officer.
Eccogene Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Eccogene's valuation, stock price, and market status.
